Lexology August 29, 2024
Alice Matthews and Adrian Toutoungi dig through the stand-out July 2024 biopharma deals. Neurodegenerative disease deals are resurgent, after a few months dominated by other therapeutic indications (and in the month that the CHMP gave a negative opinion for Biogen/Eisei’s Lequembi™). Other themes for the month included: (i) continued interest in discovery stage deals for antibody-drug conjugates (ADC), following on from our June 2024 update; and (ii) a cold wind blowing in the SHP2 inhibitor space; (iii) headwinds for AIDD-focused deals.
Deal of the month
- Roche has invested an upfront payment of $50 million in upfront and near-term milestone payments for an exclusive license to a Sangamo Therapeutics’ proprietary zinc finger repressor directed at the tau gene (and at...
Today's Sponsors
Today's Sponsor